One of Merck's pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK
Less than three months after Merck $MRK won an accelerated OK to market Keytruda as a third-line drug for stomach cancer, the pharma giant says their checkpoint failed to produce either positive overall survival data or progression-free survival results for the same indication in a second-line setting.
The pivotal Phase III flop for advanced gastric or gastroesophageal junction adenocarcinoma marks the latest in a long string of often surprising hits and misses in the checkpoint field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.